Dataset Information


Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.

ABSTRACT: Gliosarcoma is a rare histopathologic variant of glioblastoma traditionally associated with a poor prognosis. While gliosarcoma may represent a distinct clinical entity given its unique histologic composition and molecular features, its relative prognostic significance remains uncertain. While treatment of gliosarcoma generally encompasses the same standardized approach used in glioblastoma, supporting evidence is limited given its rarity. Here, we characterized 32 cases of gliosarcoma and retrospectively evaluated survival relative to 451 glioblastoma patients diagnosed during the same era within the same institution. Overall, we identified 22 primary gliosarcomas, representing 4.7% of WHO Grade IV primary glioblastomas, and 10 secondary gliosarcomas. With median age of 62, patients were predominately Caucasian (87.5%) and male (65.6%). Tumors with available molecular profiling were primarily MGMT-unmethylated (87.5%), IDH-1-preserved (100%) and EGFR wild-type (100%). Interestingly, while no significant median survival difference between primary gliosarcoma and glioblastoma was observed across the entire cohort (11.0 vs. 14.8 months, p?=?0.269), median survival was worse for gliosarcoma specifically among patients who received modern temozolomide-based (TMZ) chemoradiotherapy (11.0 vs. 17.3 months, p?=?0.006). Matched-pair analysis also trended toward worse median survival among gliosarcomas (11.0 vs. 19.6 months, log-rank p?=?0.177, Breslow p?=?0.010). While adjuvant radiotherapy (HR 0.206, p?=?0.035) and TMZ-based chemotherapy (HR 0.531, p?=?0.000) appeared protective, gliosarcoma emerged as a significantly poor prognostic factor on multivariate analysis (HR 3.27, p?=?0.012). Collectively, our results suggest that gliosarcoma may still portend worse prognosis even with modern trimodality therapy.


PROVIDER: S-EPMC7297205 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7078164 | BioStudies
2020-01-01 | S-EPMC7641818 | BioStudies
2019-01-01 | S-EPMC6468745 | BioStudies
2017-01-01 | S-EPMC5559300 | BioStudies
1000-01-01 | S-EPMC5788663 | BioStudies
1000-01-01 | S-EPMC6342854 | BioStudies
2012-01-01 | S-EPMC3424214 | BioStudies
2015-01-01 | S-EPMC4482861 | BioStudies
2019-01-01 | S-EPMC6858950 | BioStudies
1000-01-01 | S-EPMC5341871 | BioStudies